ASND | Ascendis Pharma A/S Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	144.00 - 156.96
52 Week Range	111.09 - 169.37
Beta	0.55
Implied Volatility	44.73%
IV Rank	22.44%
Day's Volume	439,520
Average Volume	476,483
Shares Outstanding	59,843,600
Market Cap	9,327,223,496
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-01-28

Valuation
Profitability
Growth
Health
P/E Ratio	-22.11
Forward P/E Ratio	-10.78
EPS	-7.05
1YR Price Target	149.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	879
Country	Denmark
Website	ASND

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

ASND's peers: ARGX, APLS, BGNE, AKRO, BPMC, REPL, NUVL, VTYX, UTHR, ISEE, AMLX, KRTX, DAWN, KDNY, DICE, PLRX, CRNX, ETNB, MDGL, ACLX, STOK, DNLI, GMAB, HALO, IMAB, INSM, JAZZ, LEGN, LGND, MRVI, ROIV, RPRX, TECH, TSVT, VRCA, XENE, ZLAB

*Chart delayed

Analyzing fundamentals for ASND we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ASND Fundamentals page.

Watching at ASND technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on ASND Technicals page.